<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317651</url>
  </required_header>
  <id_info>
    <org_study_id>SPECIALK</org_study_id>
    <nct_id>NCT04317651</nct_id>
  </id_info>
  <brief_title>Crizotinib in ALK Rearranged Non-small-cell Lung Cancer</brief_title>
  <acronym>SPECIALK</acronym>
  <official_title>Crizotinib in ALK Rearranged Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Ricerca Traslazionale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Ricerca Traslazionale</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, observational, retrospective cohort study aimed at assessing the
      efficacy and safety of crizotinib in ALK positive NSCLC treated in real life setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary efficacy objective:

      To assess the efficacy of crizotinib in real life setting

      Secondary objectives:

        1. To evaluate the therapeutic response to crizotinib-based treatment

        2. To identify additional biomarkers selectively present in the ALK positive population

        3. To assess the safety of crizotinib (250 mg/bid) in the treatment of NSCLC in real life
           setting

      Non-small-cell Lung Cancer (NSCLC) remains the leading cause of cancer death in Western
      Countries. Identification of anaplastic lymphoma kinase (ALK) gene rearrangements reinforced
      the role of targeted therapies in lung cancer. The EML4-ALK fusion gene is detected in 3-7%
      of patients with adenocarcinomas of the lung and is associated with specific clinical
      pathological features, including young age, absent or minimal smoking history and
      adenocarcinoma histology. However, such clinical features do not properly select patients for
      ALK inhibitors (ALK-Is) and, consequently, molecular testing is mandatory. Indeed, current
      guidelines recommend to test ALK rearrangements at diagnosis all patients with advanced lung
      adenocarcinoma, due to immediate therapeutic implications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sistematic review of medical records</measure>
    <time_frame>Six months</time_frame>
    <description>To assess the overall efficacy of crizotinib (250 mg/bid) in terms of Response rate, Progression-Free Survival and Overall Survival in the treatment of NSCLC in real life setting. Median PFS, as reported by a recent metanalysis, is 9.4 months (first and second line together) corresponding to a 12 months PFS rate of about 40%. The analysis of 500 patients will allow to estimate the median PFS with a semi-width 95% confidence interval of 1.2 months. OS will be calculated from the first day of treatment until the date of death from any cause. Any patient not known to have died at the time of data analysis will be censored at the time of the last recorded date on which the patient was known to be alive. Time to events will be summarized using Kaplan-Meier estimation.
ORR, defined as the proportion of patients with a best overall response of either Complete response or Partial response, will be calculated based on disease status evaluated by the investigator according to RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives</measure>
    <time_frame>Six months</time_frame>
    <description>To define clinical and biological characteristics of patients not responding to crizotinib therapy at the first tumor assessment versus individuals with complete or deep partial response (&gt; 50% reduction in the sum of target lesions)
To define additional biomarkers selectively present in the ALK positive population
To explore outcome of individuals with brain metastases
To define timing of local ablative therapy in presence of brain metastas</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with crizotinib at the standard doses of 250 mg/bid. Based on the total
        number of patients treated with Crizotinib in the NPU program (approximately 900) as well
        as on the clinical experience, the investigators expect that almost 500 patients will enter
        this study and that tumor biopsies will be available on approximately 100 patients.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Males and Females aged 18 years with diagnosis of advanced or metastatic NSCLC

          -  2. Former participation in the Italian NPU program between December 2010 - April 2013
             or receiving crizotinib according to 648 legislative Decrete from April 2013 to
             February 2015 and thereafter in clinical practice up to December 31st, 2017.

          -  3. Ascertained compliance to the Crizotinib therapy as prescribed by the relevant
             physician

          -  4. ALK rearrangement report including details of method and cutoff used for ALK
             testing

          -  5. Data on prior therapies

          -  6. Data on toxicity

          -  7. Data on crizotinib therapy efficacy including response to the therapy and survival

          -  8. Data on site of metastases

          -  9. Availability of archival tissue (not mandatory)

          -  10. Signed Informed Consent for alive and contactable patients

        Exclusion Criteria:

          -  1. Lack of clinical data

          -  2. No evidence of ALK rearrangemement

          -  3. Early death defined as fatal outcome within 30 days since the first crizotinib dose

          -  4. Absence of any radiological assessment

          -  5. No data on crizotinib efficacy including survival
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Federico Cappuzzo, MD</last_name>
    <phone>089301545</phone>
    <email>f.cappuzzo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorenza Landi, MD</last_name>
    <phone>089301545</phone>
    <email>landi.lorenza@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Versilia</name>
      <address>
        <city>Camaiore</city>
        <state>Lucca</state>
        <zip>55041</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Camerini, MD</last_name>
      <email>andrea.camerini@uslnordovest.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Camerini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Luigi Cortinovis, MD</last_name>
      <email>d.cortinovis@asst-monza.it</email>
    </contact>
    <investigator>
      <last_name>Diego Luigi Cortinovis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata</name>
      <address>
        <city>Rionero In Vulture</city>
        <state>Potenza</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Aieta, MD</last_name>
      <email>michele.aieta@crob.it</email>
    </contact>
    <investigator>
      <last_name>Michele Aieta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>Ravenna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Delmonte, MD</last_name>
      <phone>0543 739100</phone>
      <email>angelo.delmonte@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Delmonte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Novello, MD</last_name>
      <phone>0119026978</phone>
      <email>silvia.novello@unito.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Novello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacro Cuore- Don Calabria Hospital</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefania Gori, MD</last_name>
      <phone>0456013472</phone>
      <email>stefania.gori@sacrocuore.it</email>
    </contact>
    <investigator>
      <last_name>Stefania Gori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;S.G. Moscati&quot;</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Gridelli, MD</last_name>
      <phone>0825 203945 - 203573</phone>
      <email>cgridelli@libero.it</email>
    </contact>
    <investigator>
      <last_name>Cesare Gridelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Galetta, MD</last_name>
      <phone>0805555418</phone>
      <email>galetta@teseo.it</email>
    </contact>
    <contact_backup>
      <last_name>Sandro Cassiano, Ph</last_name>
      <email>sandrocassiano@libero.it</email>
    </contact_backup>
    <investigator>
      <last_name>Domenico Galetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Mazzoni, MD</last_name>
      <email>francescamazzoni@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Francesca Mazzoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Papardo</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Adamo, MD</last_name>
      <phone>+390903996150</phone>
      <email>vadamo@unime.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Adamo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Spitalieri, MD</last_name>
      <phone>+39 02 94372730</phone>
      <email>gianluca.spitaleri@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Spitalieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N dei Colli - Ospedale Monaldi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francovito Piantedosi, MD</last_name>
      <phone>0817064086/65213</phone>
      <email>fvpiantedosi1@tin.it</email>
    </contact>
    <investigator>
      <last_name>Francovito Piantedosi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Morabito, MD</last_name>
      <phone>081-5903631</phone>
      <email>a.morabito@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Morabito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Giovanni Paolo II ASL-2 Olbia</name>
      <address>
        <city>Olbia</city>
        <zip>07026</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Sini</last_name>
      <email>audiosini@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Sini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bonanno, MD</last_name>
      <email>laura.bonanno@iov.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Laura Bonanno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Del Maso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Tiseo, MD</last_name>
      <phone>0521702316-702682</phone>
      <email>mtiseo@ao.pr.it</email>
    </contact>
    <investigator>
      <last_name>Marcello Tiseo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia - Azienda Ospedaliera di Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fausto Roila, MD</last_name>
      <email>roila.fausto@libero.it</email>
    </contact>
    <investigator>
      <last_name>Fausto Roila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenza Landi, MD</last_name>
      <email>landi.lorenza@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Michela Spreafico, Biologist</last_name>
      <phone>0544286223</phone>
      <email>michela.spreafico@irst.emr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Lorenza Landi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS- Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pagano, MD</last_name>
      <email>Maria.Pagano@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Maria Pagano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario &quot;Campus Biomedico&quot; di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Tiseo, MD</last_name>
      <email>g.tonini@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tiseo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo-Forlanini</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rita Migliorino, MD</last_name>
      <phone>0658704670</phone>
      <email>mmigliorino@scamilloforlanini.rm.it</email>
    </contact>
    <investigator>
      <last_name>Maria Rita Migliorino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Sette Laghi &quot;Ospedale di Circolo e Fondazione Macchi&quot;</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Tuzi, MD</last_name>
      <email>alessandro.tuzi@asst-settelaghi.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Tuzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico 'G.B.Rossi' Borgo Roma - Azienda Ospedaliera Universitaria Integrata (Giampaolo Tortora)</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Santo, MD</last_name>
      <email>antonio.santo@aovr.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Santo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>crizotinib</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Advanced Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>ALK positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

